Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions

Abstract

Libraries of immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind.

1 - 6 . (canceled) 
     
     
         7 . An isolated nucleic acid encoding a polypeptide scaffold comprising an immunoglobulin fold of a constant domain comprising six structural loops connected by beta strands, three of said six structural loops corresponding to three structural loops of a human IgG1 constant region CH3 domain, said three structural loops of said human IgG1 constant region CH3 domain consisting of the AB loop at positions 17-19, the CD loop at positions 44-47, and the EF loop at positions 71-73 and 76-77 of SEQ ID NO:1, wherein said scaffold comprises no more than 21 residue changes in the corresponding residues of said native human IgG1 constant region CH3 domain; and
 wherein said scaffold comprises a minimum number of residues which differ from corresponding residues of SEQ ID NO: 1 selected from the group consisting of:
 a) wherein two or more of said three structural loops of said scaffold comprise a total of at least three residues which are different from corresponding residues of SEQ ID NO: 1; 
 and/or 
 b) wherein one of said three structural loops of said scaffold comprise at least four residues which are different from corresponding residues of SEQ ID NO: 1; and 
   wherein said structural loops of said polypeptide scaffold form a solvent accessible surface.   
     
     
         8 . The nucleic acid of  claim 7 , wherein said scaffold comprises at least 6 residue changes in the corresponding residues of said native human IgG1 constant region CH3 domain. 
     
     
         9 . The nucleic acid of  claim 7 , wherein said scaffold comprises at least 11 residue changes in the corresponding residues of said native human IgG1 constant region CH3 domain. 
     
     
         10 . The nucleic acid scaffold of  claim 7 , wherein in (a) each of said two or more of said three structural loops of said scaffold comprises at least three residues which are different from corresponding residues of SEQ ID NO: 1. 
     
     
         11 . The nucleic acid of  claim 7 , wherein said structural loops of (a) and (b) of  claim 7 , do not comprise an inserted peptide of predetermined sequence that specifically binds an epitope independently of its insertion into said structural loops of (a) and/or (b). 
     
     
         12 . The nucleic acid of  claim 7 , wherein said scaffold comprises an amino acid sequence selected from the group consisting of: SEQ ID NO: 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40 and 42. 
     
     
         13 . (canceled) 
     
     
         14 . A host cell comprising the nucleic acid of  claim 7 . 
     
     
         15 . (canceled) 
     
     
         16 . A vector comprising the nucleic acid of  claim 7 . 
     
     
         17 . (canceled) 
     
     
         18 . The vector of  claim 16 , wherein said vector is an expression vector. 
     
     
         19 . (canceled) 
     
     
         20 . The host cell of  claim 14  wherein said host cell is selected from the group consisting of mammalian cells, plant cells, bacteria, insect cells, and yeast. 
     
     
         21 . (canceled) 
     
     
         22 . The host cell of  claim 20 , wherein said bacteria is  Bacillus subtilis  or  Escherichia coli.    
     
     
         23 . (canceled) 
     
     
         24 . The host cell of  claim 20 , wherein said yeast is  Pichia pastoris  or  Saccharomyces cerevisiae.    
     
     
         25 . (canceled) 
     
     
         26 . The vector of  claim 16 , wherein said vector is a viral vector or a phage vector. 
     
     
         27 . The nucleic acid of  claim 7 , wherein said scaffold comprises no more than 16 residue changes in the corresponding residues of said native human IgG1 constant region CH3 domain.